Clinical Trial Update: PT-112 in Subjects With Thymoma and Thymic Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating PT-112 in patients with thymoma and thymic carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma

Drugs mentioned

• PT-112

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Thymic Epithelial Tumor, Recurrent Thymoma | Phase 2 | Status: RECRUITING